News headlines about Evoke Pharma (NASDAQ:EVOK) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Evoke Pharma earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.0617971483488 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
- Evoke Pharma : Reports Third Quarter 2017 Results and Highlights (4-traders.com)
- A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector (finance.yahoo.com)
- Evoke Pharma, Inc. to Host Earnings Call (finance.yahoo.com)
- Evoke Pharma Reports Third Quarter 2017 Results and Highlights (finance.yahoo.com)
- Evoke Pharma : Evokes experience with Thermo wins Patheon nasal metoclopramide contract (4-traders.com)
Several research firms have recently weighed in on EVOK. FBR & Co reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research report on Monday, October 30th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a research report on Tuesday, October 24th. Northland Securities reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research report on Wednesday, October 18th. Zacks Investment Research raised shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 12th. Finally, Seaport Global Securities reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $8.86.
Shares of Evoke Pharma (NASDAQ:EVOK) traded up $0.01 during trading hours on Tuesday, hitting $2.81. 76,400 shares of the company were exchanged, compared to its average volume of 429,734. Evoke Pharma has a twelve month low of $1.42 and a twelve month high of $4.55.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). During the same quarter last year, the company earned ($0.29) EPS. research analysts expect that Evoke Pharma will post -0.79 earnings per share for the current year.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.